Latest / The Well-Built Life / Reviving Neurons: Potential Alzheimer’s Breakthrough
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:06Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple, practical habits that help you feel stronger, healthier,
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:22Speaker 1: and let's dive in. Welcome, Thomas. Let's dive into some
- 0:25Speaker 1: groundbreaking work on Alzheimer's disease. Scientists have developed a treatment
- 0:31Speaker 1: that aims to regenerate neurons, not just slow the disease's progression.
- 0:37Speaker 1: What do you think the significance of this might be?
- 0:40Speaker 2: Absolutely, Rachel. This shift from symptom management to actual cell
- 0:44Speaker 2: repair is a game changer. The current treatments are good,
- 0:48Speaker 2: but they are like a band-aid on a bullet wound.
- 0:51Speaker 2: They can ease temporary symptoms and slow down the disease,
- 0:54Speaker 2: but they can't reverse much damage. This nano-eraser treatment seems
- 0:58Speaker 2: to go straight to the root of the problem.
- 1:01Speaker 1: That's right. Existing treatments focus primarily on targeting the beta-amyloid
- 1:06Speaker 1: plaques and neurofibrillary tangles. But the real damage in Alzheimer's
- 1:11Speaker 1: comes from the loss of neurons that facilitate communication within
- 1:15Speaker 1: the brain. Without these cells, the brain can't recover from
- 1:18Speaker 1: the trauma, and current therapies can't bring them back.
- 1:22Speaker 2: Exactly. This nano-eraser approach is interesting because it specifically targets
- 1:27Speaker 2: a protein called PTBP1. By reducing PTBP1, the treatment encourages
- 1:35Speaker 2: astrocytes to turn into neurons. Astrocytes are support cells in
- 1:39Speaker 2: the brain, often described as caretakers of neurons. They are
- 1:43Speaker 2: quite common and can be easily reached by the treatment,
- 1:47Speaker 2: making it more feasible to deliver the necessary changes.
- 1:50Speaker 1: Right. Speaking of feasibility … This sounds like an ambitious goal.
- 1:55Speaker 1: Have they actually tested this in mice? And if so,
- 1:58Speaker 1: what results did they get?
- 2:00Speaker 2: Yes, they did extensive testing. In their experiments, eight-month-old mice,
- 2:05Speaker 2: which are similar to mid-stage Alzheimer's patients, received two injections,
- 2:09Speaker 2: eight days apart. After treatment, the mice showed significant improvements
- 2:13Speaker 2: in nest building and maze tests, which are proxies for
- 2:17Speaker 2: memory and cognitive function. The researchers also noted a presence
- 2:21Speaker 2: of new and mature neurons in the brain, unlike in
- 2:24Speaker 2: previous treatments.
- 2:26Speaker 1: Those are impressive results, but let's not get too excited yet.
- 2:30Speaker 1: Small animal studies are just the beginning. What else did
- 2:34Speaker 1: the researchers find?
- 2:35Speaker 2: They observed other positive changes as well, like reduced levels
- 2:40Speaker 2: of inflammatory molecules and amyloid beta, which is the protein
- 2:44Speaker 2: responsible for forming plaques in Alzheimer's. These changes suggest that
- 2:48Speaker 2: the treatment affects more than just neurons. It seems to
- 2:51Speaker 2: have a broader impact on the neuroinflammation and the buildup
- 2:55Speaker 2: of harmful proteins. Yes.
- 2:57Speaker 1: The full scope of this treatment is exciting, but Taree's
- 3:00Speaker 1: still a long way to go. They haven't conducted human
- 3:04Speaker 1: trials yet and need to address several questions. How do
- 3:07Speaker 1: we know where these new neurons are coming from, and
- 3:10Speaker 1: how does this intervention fit into the larger circuitry of
- 3:13Speaker 1: the brain?
- 3:14Speaker 2: Great questions, Rachel. The researchers have acknowledged that more work
- 3:18Speaker 2: is needed to clarify these points. They are looking into
- 3:21Speaker 2: the longevity of the treatment, its safety, and the optimal dosage.
- 3:25Speaker 2: The next steps are crucial to understanding whether these benefits
- 3:29Speaker 2: can be sustained over time, and if the new neurons
- 3:33Speaker 2: integrate effectively into existing neural networks.
- 3:36Speaker 1: That sounds like a lot of work ahead. But the concept, Thomas,
- 3:40Speaker 1: of being able to reverse the damage rather than just
- 3:42Speaker 1: managing it, is thrilling. If this approach works, we could
- 3:47Speaker 1: be looking at a revolutionary new way to treat Alzheimer's.
- 3:50Speaker 2: Indeed. And remember, this is just one potential path. If
- 3:55Speaker 2: the treatment proves effective in humans, it could be a
- 3:58Speaker 2: cornerstone in a broader strategy for Alzheimer's management and prevention.
- 4:03Speaker 2: The journey from lab mice to patient care isn't easy,
- 4:06Speaker 2: but the breakthroughs could be groundbreaking.
- 4:08Speaker 1: So, Thomas, let's break down the nano-eraser mechanism. It's fascinating
- 4:14Speaker 1: how they target PTBP1, isn't it?
- 4:17Speaker 2: Absolutely, Rachel. PTBP1 is a key player. It's usually responsible
- 4:23Speaker 2: for keeping astrocytes in their support role. But by removing it,
- 4:27Speaker 2: they allow these astrocytes to develop characteristics of neurons.
- 4:31Speaker 1: And how does the nano-eraser system actually perform this removal?
- 4:36Speaker 1: Is there a specific process?
- 4:37Speaker 2: Yes. Therese Precision involved. The nanoparticles carry a payload that
- 4:42Speaker 2: specifically targets PTBP1. Once inside the astrocytes, these nanoparticles degrade PTB1,
- 4:50Speaker 2: allowing the cells to transform.
- 4:52Speaker 1: That's intricate. And what happened in the human cell cultures?
- 4:56Speaker 1: Did they really start to look like neurons? Exactly.
- 4:59Speaker 2: In the lab, the cells showed remarkable changes. They started
- 5:03Speaker 2: producing proteins typically found in neurons. And even some electrical
- 5:07Speaker 2: tests suggested they could function like neurons.
- 5:10Speaker 1: So, essentially, the cells are reprogramming themselves? That's pretty revolutionary.
- 5:16Speaker 1: But how do those new neurons fit into the existing network?
- 5:19Speaker 2: Great question. The treatment isn't just about creating new cells.
- 5:24Speaker 2: It's about integrating them into the existing network. The researchers
- 5:29Speaker 2: observed that these new neurons formed connections, which suggests they
- 5:33Speaker 2: could become part of the brain's complex circuits.
- 5:36Speaker 1: And that's significant because, historically, it's been really hard to
- 5:40Speaker 1: get new neurons to integrate properly. This could be the
- 5:43Speaker 1: difference between just treating symptoms and truly reversing the damage.
- 5:48Speaker 2: Right. And it went beyond just the lab. They tested
- 5:51Speaker 2: the treatment in mice with Alzheimer's-like symptoms, and the results
- 5:55Speaker 2: were impressive. The mice started building nests better and performed
- 5:59Speaker 2: better in memory tests.
- 6:00Speaker 1: That's wild when you look at the raw numbers. It
- 6:03Speaker 1: almost feels like a turning point In Alzheimer's research.
- 6:06Speaker 2: Absolutely. But the journey isn't over. The researchers still need
- 6:11Speaker 2: to find out exactly where these new neurons are coming
- 6:14Speaker 2: from and whether the benefits are long-lasting. And remember, this
- 6:18Speaker 2: is in mice. Human trials could bring a whole new
- 6:21Speaker 2: set of challenges. True.
- 6:23Speaker 1: The road to clinical application will be filled with hurdles,
- 6:27Speaker 1: but this is a promising start. If it does work,
- 6:31Speaker 1: the implications could be huge for Alzheimer's patients.
- 6:34Speaker 2: Indeed. And this isn't the only potential path. It's just
- 6:39Speaker 2: one piece of the puzzle in a broader strategy. But still,
- 6:43Speaker 2: this breakthrough could change the game.
- 6:45Speaker 1: Right, so let's dive into the results. The study showed
- 6:49Speaker 1: significant improvements in cognitive functions, neuronal development, and even some
- 6:53Speaker 1: reduction in inflammation in mice. But Therese, a lot we
- 6:57Speaker 1: need to unpack here.
- 6:58Speaker 2: Absolutely. Let's start with those cognitive improvements. The mice were
- 7:03Speaker 2: better at building nests and performing in water mazes. How
- 7:07Speaker 2: does that translate to memory function?
- 7:09Speaker 1: Well, these tests are fairly basic. They give us a
- 7:13Speaker 1: crude way to measure learning and memory. But the real
- 7:17Speaker 1: question is how this compares to existing treatments.
- 7:20Speaker 2: That's a great point. Existing treatments like aducanumab and donatase
- 7:25Speaker 2: typically focus on reducing beta-amyloid plaque formation and inflammatory processes.
- 7:31Speaker 2: They show some promising results, but are far from a cure.
- 7:35Speaker 2: How does nano-eraser stack up?
- 7:37Speaker 1: The researchers noted that the cognitive improvements seen in the
- 7:41Speaker 1: treated mice were more comprehensive. They weren't just slowing the disease,
- 7:46Speaker 1: but actually regenerating neurons. That's a game-changer.
- 7:50Speaker 2: Exactly. The neurogenesis aspect is crucial. It means the brain
- 7:54Speaker 2: is not just holding on, but actively rebuilding itself. That's
- 7:59Speaker 2: a stark contrast to what we have seen with existing treatments. However,
- 8:04Speaker 2: the study notes that the new neurons might be integrated
- 8:06Speaker 2: into existing circuits.
- 8:08Speaker 1: That brings up an interesting dynamic. If new neurons are
- 8:12Speaker 1: added without fully integrating into the existing network, their benefit
- 8:16Speaker 1: could be limited. It's like adding new blocks to a
- 8:19Speaker 1: building that still has structural issues. It might support the surface,
- 8:25Speaker 1: but the foundation is weak.
- 8:27Speaker 2: True. And the study's limitation in terms of long-term stability
- 8:31Speaker 2: is significant. The researchers suggest further work to establish how
- 8:35Speaker 2: permanent these changes are. That's where things get tricky, especially
- 8:39Speaker 2: considering the complexity of the human brain.
- 8:42Speaker 1: Speaking of complexity, the inflammatory reduction is also fascinating. Inflammation
- 8:48Speaker 1: has been linked to neurodegeneration, but how does nano-eraser manage
- 8:53Speaker 1: to reduce it? It seems to have a dual mechanism
- 8:56Speaker 1: at play. Right.
- 8:58Speaker 2: The treatment targets PTBP1 removal, which allows astrocytes to take
- 9:03Speaker 2: on some neuronal characteristics. This isn't just about inflammation reduction.
- 9:08Speaker 2: It's about reprogramming cell behavior. It's a bit like retraining
- 9:12Speaker 2: old soldiers to fight in a different way.
- 9:14Speaker 1: Exactly. Reprogramming. Instead of just managing symptoms. That's what sets
- 9:19Speaker 1: nano or razor apart. But we can't ignore the practical
- 9:23Speaker 1: realities either. The treatment has only been tested in mice.
- 9:27Speaker 1: and human trials are still a ways off.
- 9:30Speaker 2: Indeed, there are many hurdles to overcome, but the initial
- 9:34Speaker 2: results are promising. It's a powerful step forward, but we
- 9:37Speaker 2: need to tread cautiously. Each new result raises more questions
- 9:41Speaker 2: than answers, and that's where the real excitement lies. Agreed.
- 9:46Speaker 1: The next phase will be crucial in determining whether this
- 9:49Speaker 1: can translate to meaningful results in humans. For now, it's
- 9:53Speaker 1: a beacon of hope and a reminder that Alzheimer's research
- 9:57Speaker 1: is moving in a new, exciting direction. So, Thomas, shifting gears,
- 10:01Speaker 1: the next big question is just where these new neurons
- 10:04Speaker 1: are coming from. It's an interesting conundrum. They don't seem
- 10:08Speaker 1: to be creating new neurons de novo, but something is
- 10:11Speaker 1: happening to encourage astrocytes to take on more neuronal characteristics.
- 10:16Speaker 1: How does that work exactly?
- 10:18Speaker 2: Exactly. Which is where the real magic may lie. You see,
- 10:22Speaker 2: the key lies in the PTBP1 protein. When researchers knock
- 10:26Speaker 2: it out, astrocytes start sprouting characteristics similar to neurons, like
- 10:30Speaker 2: producing proteins that neurons typically make. But remember, neurons are
- 10:34Speaker 2: supposed to be a rare cell type. Turning astrocytes into
- 10:38Speaker 2: neurons could involve reprogramming, or, as some speculate, a reactive
- 10:43Speaker 2: elemental pathways.
- 10:44Speaker 1: That's fascinating. If it's a reactivation... Is this just a
- 10:48Speaker 1: temporary change? Or do these cells somehow revert back to
- 10:52Speaker 1: their original state? How do they decide which path to take?
- 10:56Speaker 2: Ah, great question. The answer seems to be that it's
- 10:59Speaker 2: a bit of both. The environment and signals they receive
- 11:03Speaker 2: play a huge role. For instance, the absence of PTBP1
- 11:09Speaker 2: might create the right conditions to switch off certain neuron,
- 11:12Speaker 2: specific genes, and switch on others. This is a dynamic
- 11:16Speaker 2: process rather than a one-way street. It's also worth noting
- 11:20Speaker 2: that the long-term commitment of these cells is still uncertain.
- 11:25Speaker 2: They might revert back to astrocytes, or maintain a hybrid
- 11:28Speaker 2: state depending on the ongoing signals they receive post-treatment.
- 11:33Speaker 1: Wait, but how does that actually play out in practice?
- 11:36Speaker 1: Are they looking at specific neural pathways, micornas, or other
- 11:40Speaker 1: epigenetic modifications to track this process?
- 11:43Speaker 2: Precisely. The researchers are delving deep into epigenetics and microRNAs
- 11:48Speaker 2: to understand these changes. For example, there are specific microRNAs
- 11:52Speaker 2: and transcription factors that seem to be involved in the
- 11:55Speaker 2: process of reprogramming. They are exploring how changing the expression
- 11:59Speaker 2: of these factors might affect the cell's fate. Plus, they
- 12:03Speaker 2: are looking at the signaling pathways that could be involved
- 12:06Speaker 2: in maintaining the neuronal-like state after PTBP1 is removed.
- 12:11Speaker 1: That's wild when you look at the raw numbers. But
- 12:14Speaker 1: what about the duration of this effect? Will the benefits linger,
- 12:19Speaker 1: or is it just short-lived?
- 12:21Speaker 2: That's the billion-dollar question right now. Initial results are promising,
- 12:26Speaker 2: but as we know, mice aren't humans. The treatment has
- 12:30Speaker 2: only been administered twice, and the effects seem to persist
- 12:33Speaker 2: for a while, but the long-term stability is still under investigation.
- 12:38Speaker 2: The researchers are conducting long-term follow-up studies to assess whether
- 12:42Speaker 2: these new neurons become integrated into existing brain circuits and
- 12:47Speaker 2: whether the cognitive improvements are sustainable.
- 12:49Speaker 1: Right. And this is not just about reversing memory loss.
- 12:53Speaker 1: It's about potentially reversing the underlying pathology of Alzheimer's. If
- 12:58Speaker 1: these findings hold up, the implications for treatment are enormous.
- 13:02Speaker 1: Imagine the impact on quality of life for millions of people.
- 13:06Speaker 2: Absolutely, Rachel. It's a thrilling prospect. If successful, this could
- 13:11Speaker 2: shift the paradigm from just managing symptoms to actually repairing
- 13:15Speaker 2: the damage. That's a big deal. Of course, we must
- 13:20Speaker 2: remain cautious and not get ahead of ourselves. Plenty of
- 13:24Speaker 2: challenges lie ahead, but the potential is exhilarating.
- 13:27Speaker 1: Right, and this is where the real game changer comes in.
- 13:30Speaker 1: The nano-eraser treatment not only targets the cellular level... but
- 13:36Speaker 1: also addresses the root of the issue, neuron loss. By
- 13:39Speaker 1: removing PTBP1, the treatment prompts astrocytes to transform into neurons,
- 13:46Speaker 1: potentially offering a pathway to regeneration rather than just symptom management.
- 13:52Speaker 2: Exactly, Rachel. This is a turning point. The regeneration aspect
- 13:56Speaker 2: is transformative. We have seen treatments that focus on slowing
- 14:00Speaker 2: cognitive decline. but having the capability to potentially repair the
- 14:04Speaker 2: brain structure is revolutionary. Think of it as flipping the
- 14:08Speaker 2: script from reactive to proactive. It's not just about managing
- 14:12Speaker 2: the symptoms, it's about fundamentally reversing the disease's progression.
- 14:16Speaker 1: That's right, and the implications for public perception are significant.
- 14:21Speaker 1: Alzheimer's is often seen as an unsolvable, inevitable part of aging.
- 14:26Speaker 1: This research could shift that narrative, making Alzheimer's a condition
- 14:31Speaker 1: that is not only treatable but potentially even curable, the
- 14:34Speaker 1: public's response will be crucial in driving further investment and
- 14:38Speaker 1: attention to this treatment.
- 14:40Speaker 2: Absolutely. And that's where the tricky part lies. We need
- 14:44Speaker 2: to manage public expectations. While the results in mice are promising,
- 14:49Speaker 2: we are still far from the clinic. The treatment must
- 14:52Speaker 2: prove its efficacy in larger clinical trials. People have suffered
- 14:56Speaker 2: enough disappointment from early optimism that doesn't translate into actual benefits. So,
- 15:02Speaker 2: it's important to approach this with the right balance of
- 15:04Speaker 2: excitement and caution.
- 15:06Speaker 1: Very true. And from a therapeutic standpoint, there is a
- 15:09Speaker 1: lot of work to be done on the logistics and
- 15:12Speaker 1: side effects. For instance, understanding exactly where the new neurons
- 15:16Speaker 1: come from, whether they are created de novo or co-opted
- 15:20Speaker 1: from existing cells, will be critical. Also, The long-term effects
- 15:25Speaker 1: and sustainability of the treatment need to be thoroughly investigated.
- 15:29Speaker 2: And then Therese, the economic and healthcare system angle. Imagine
- 15:33Speaker 2: the logistics of dosing millions of patients. The scale of
- 15:36Speaker 2: treatment and follow-up care will be enormous. Pharmaceutical companies might
- 15:40Speaker 2: see great investment potential, but ensuring equitable access will be
- 15:44Speaker 2: a significant challenge. We must prepare for both the excitement
- 15:48Speaker 2: and the real-world complexities.
- 15:50Speaker 1: Absolutely. On a broader scale, This breakthrough could lead to
- 15:54Speaker 1: shifting paradigms in neurodegenerative diseases. Beyond Alzheimer's, the approach might
- 16:00Speaker 1: be adaptable to other conditions affecting the brain, like Parkinson's
- 16:04Speaker 1: or even spinal cord injuries. The potential is vast, and
- 16:08Speaker 1: this research opens exciting doors for future studies.
- 16:11Speaker 2: Indeed, and with every step, we will need to carefully
- 16:15Speaker 2: navigate the ethical and practical challenges. Ensuring the treatment is
- 16:20Speaker 2: safe and effective. Making it accessible and addressing the economic
- 16:24Speaker 2: and social impacts will be key. It's an ambitious journey,
- 16:29Speaker 2: but the prospects are incredibly promising.
- 16:31Speaker 1: That brings us to the end of today's episode. Thank
- 16:34Speaker 1: you so much for spending part of your day with me.
- 16:36Speaker 1: If you found this episode's tips helpful and want to
- 16:39Speaker 1: make sure you don't miss the next conversation, please take
- 16:42Speaker 1: a quick second to hit that subscribe or follow button
- 16:45Speaker 1: on whatever platform you are listening on. It's a completely
- 16:48Speaker 1: free way to support the show and helps more people
- 16:51Speaker 1: find us. This podcast is independently produced, so if you
- 16:55Speaker 1: are ever in a position where you would like to
- 16:57Speaker 1: help keep it running, we do accept small donations. You
- 17:01Speaker 1: can find a link right in the episode description below
- 17:03Speaker 1: to buy us a coffee or contribute what you can.
- 17:06Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 17:11Speaker 1: and we will talk again soon.